(Q33790182)

29 July 2017

1 reference

title

Adjuvant tamoxifen: how long before we know how long? (English)

1 reference

29 July 2017

1 reference

Rea D

1

1 reference

29 July 2017

Poole C

series ordinal

2

1 reference

29 July 2017

Gray R

series ordinal

3

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 May 1998

1 reference

29 July 2017

1 reference

29 July 2017

316

1 reference

29 July 2017

1518-1519

1 reference

29 July 2017

7143

1 reference

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

29 July 2017

1 reference

PubMed Central

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1113163

Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group

28 July 2018

1 reference

PubMed Central

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1113163

Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee

28 July 2018

1 reference

PubMed Central

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1113163

Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group

28 July 2018

1 reference

12 December 2020

Bone mineral density in women with breast cancer treated with adjuvant tamoxifen for at least two years

1 reference

12 December 2020

Sudden fall in breast cancer death rates in England and Wales

1 reference

12 December 2020

Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors

1 reference

12 December 2020

Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. Swedish Breast Cancer Cooperative Group

1 reference

12 December 2020

Five years of tamoxifen--or more?

1 reference

12 December 2020

Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group

1 reference

12 December 2020

Preliminary Results From the Cancer Research Campaign Trial Evaluating Tamoxifen Duration in Women Aged Fifty Years or Older With Breast Cancer

1 reference

12 December 2020

10.1136/BMJ.316.7143.1518

Identifiers

DOI

1 reference

29 July 2017

1 reference

29 July 2017

1 reference